|
NR. 3(II)/2007
|
|
|
|
|
|
|
|
|
Zastosowanie
selektywnych α2-mimetyków w terapii jaskry
Selective α2-mimetics Use in Glaucoma Therapy
Magdalena Pilas-Pomykalska, Anna
Wyrwicka, Joanna Juszczyk, Dorota Tomaszkiewicz-Mondry, Janusz
Czajkowski
Klinika Okulistyki Instytutu „Centrum Zdrowia Matki Polki” w
Łodzi
Kierownik: prof. dr hab. n. med. Janusz Czajkowski |
|
|
|
|
|
|
|
| Summary: |
The authors present the
application of high selective α2-mimetics in glaucoma
therapy. 0.2% briminidine tartrate (Alphagan) belongs to
3rd generation of α2agonists with the highest
selectivity to α2receptors. Brimonidine reduces IOP in
two ways: by aqueous humor production reduction and
uveoscleral outflow increase. Alphagan is useful as
monotherapy with efficacy similar to non-selective
β-blockers or as adjunctive treatment. The authors
discuss its indications, efficacy, safety and side
effects in glaucoma treatment. |
| |
|
| Key words: |
α2-mimetics, brimonidine,
glaucoma treatment. |
|
|
|
|
|
|
|
|
